Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Palvella wins FDA fast track status for QTORIN rapamycin gel in angiokeratomas

Palvella Therapeutics (NASDAQ:PVLA) said the U.S. Food and Drug Administration has granted Fast Track Designation to QTORIN 3.9% rapamycin anhydrous gel for treating angiokeratomas, a dermatologic condition with no currently approved therapies.

Leia mais: Palvella wins FDA fast track status for QTORIN rapamycin gel in angiokeratomas
Grafa
Health

Nektar’s alopecia drug shows hair-regrowth benefit but misses primary endpoint in Phase 2b trial

Nektar Therapeutics (NASDAQ:NKTR) reported mixed Phase 2b results for rezpegaldesleukin in severe-to-very-severe alopecia areata, showing meaningful clinical activity but narrowly missing the trial’s primary endpoint in the modified intent-to-treat population.

Leia mais: Nektar’s alopecia drug shows hair-regrowth benefit but misses primary endpoint in Phase 2b trial